ORLANDO — Early treatment with Izervay demonstrated increased efficacy in slowing geographic atrophy lesion growth over time, according to a study.
Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates, presented results from the GATHER2 open-label extension study at Retina Subspecialty Day at the American Academy of Ophthalmology meeting.
{{VIDEO}}
GATHER2 was a 2-year trial that assessed the safety and efficacy of Izervay (avacincaptad pegol, Astellas) in patients with geographic atrophy. In the open-label extension study, patients who received avacincaptad pegol (ACP) monthly or every